Slides
Page 1
Investor Presentation | Q3FY26 January 23rd, 2026
Page 2
1 Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will" , "aim" , "will likely result" , "would" , "believe" , "may" , "expect" , "will continue" , "anticipate" , "estimate" , "intend" , "plan" , "contemplate" , “seek to" , "future" , "objective" , "goal" , "likely" , "project" , "should" , "potential" , "will pursue" , and similar expressions of such expressions may constitute "forward-looking statements“ . These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially f rom those suggested by the forward- looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
Page 3
Financial Performance and Business Outlook Q3FY26
Page 4
3 As previously anticipated, this has been a subdued quarter due to delays in customer approvals in Canada that have prolonged the transition from the MSA to the CSA phase. The inherent demand, however, remains intact with order book continuing to trend upwards. In our nascent biologics segment, we continue to witness strong interest, with another global biosimilar player onboarded and the funnel at a historic high. ( Q3FY26 Performance Snapshot ) ₹2,903m $33.1m ₹173m $2.0m 6% (₹472m) ($5.4m) Neeraj Sharma CEO & MD Customer approval delays weigh on Q3FY26 performance; Inherent business strength intact, FY28 guidance reaffirmed 26% YoY 88% YoY Revenue EBITDA 3,018 bps YoY EBITDA margin Adjusted PAT1 Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹87.67 1. Adjusted PAT excludes exceptional items (₹71m) and scheme related intangible amortisation (₹344m)